Lupus risk variants in the PXK locus alter B-cell receptor internalization by Samuel E. Vaughn et al.
ORIGINAL RESEARCH ARTICLE
published: 08 January 2015
doi: 10.3389/fgene.2014.00450
Lupus risk variants in the PXK locus alter B-cell receptor
internalization
Samuel E. Vaughn1,2, Corinne Foley3, Xiaoming Lu2, Zubin H. Patel1,2, Erin E. Zoller2,
Albert F. Magnusen2, Adrienne H. Williams4, Julie T. Ziegler4, Mary E. Comeau4, Miranda C. Marion4,
Stuart B. Glenn5, Adam Adler5, Nan Shen1,6, Swapan Nath5, Anne M. Stevens7,8, Barry I. Freedman9,
Betty P. Tsao10, Chaim O. Jacob11, Diane L. Kamen12, Elizabeth E. Brown13,14, Gary S. Gilkeson12,
Graciela S. Alarcón14, John D. Reveille15, Juan-Manuel Anaya16, Judith A. James5,17, Kathy L. Moser5,
Lindsey A. Criswell18, Luis M. Vilá19, Marta E. Alarcón-Riquelme5,20, Michelle Petri21,
R. Hal Scofield5,17,22, Robert P. Kimberly14, Rosalind Ramsey-Goldman23, Young Binjoo24,
Jeongim Choi24, Sang-Cheol Bae24, Susan A. Boackle25, Timothy J. Vyse26, Joel M. Guthridge5,
Bahram Namjou2, Patrick M. Gaffney5, Carl D. Langefeld4, Kenneth M. Kaufman2,27, Jennifer A. Kelly5,
Isaac T. W. Harley1,2, John B. Harley2,27 and Leah C. Kottyan2,27*
1 Immunology Graduate Program and Medical Scientist Training Program, University of Cincinnati College of Medicine, Cincinnati, OH, USA
2 Center for Autoimmune Genomics and Etiology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA
3 Spelman College, Atlanta, GA, USA
4 Center for Public Health Genomics and the Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, USA
5 Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA
6 Joint Molecular Rheumatology Laboratory of the Institute of Health Sciences and Shanghai Renji Hospital, Shanghai Jiao Tong University School of Medicine,
Shanghai Institutes for Biological Sciences, and Chinese Academy of Sciences, Shanghai, China
7 Center for Immunity and Immunotherapies, Seattle Children’s Research Institute, Seattle, WA, USA
8 Division of Rheumatology, Department of Pediatrics, University of Washington, Seattle, WA, USA
9 Department of Internal Medicine, Section on Nephrology, Wake Forest School of Medicine, Winston-Salem, NC, USA
10 Division of Rheumatology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA
11 Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
12 Division of Rheumatology, Medical University of South Carolina, Charleston, SC, USA
13 Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, USA
14 Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA
15 Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston, Houston, TX, USA
16 Center for Autoimmune Disease Research, Universidad del Rosario, Bogota, Colombia
17 Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
18 Rosalind Russell/Ephraim P Engleman Rheumatology Research Research Center, Department of Medicine, University of California, San Francisco, San Francisco,
CA, USA
19 Division of Rheumatology, Department of Medicine, University of Puerto Rico Medical Sciences Campus, San Juan, PR, USA
20 Center for Genomics and Oncological Research, Pfizer-University of Granada-Junta de Andalucia, Granada, Spain
21 Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
22 United States Department of Veterans Affairs Medical Center, Oklahoma City, OK, USA
23 Division of Rheumatology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
24 Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea
25 Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, USA
26 Divisions of Genetics and Molecular Medicine and Immunology, King’s College London, London, UK
27 United States Department of Veterans Affairs Medical Center, Cincinnati, OH, USA
Edited by:
Mariza De Andrade, Mayo Clinic,
USA
Reviewed by:
Vikas Bansal, Scripps Translational
Science Institute, USA
Kui Zhang, University of Alabama at
Birmingham, USA
*Correspondence:
Leah C. Kottyan, Center for
Autoimmune Genomics and
Etiology, Cincinnati Children’s
Hospital Medical Center, 3333
Burnet Ave., Mail Location 15012,
Cincinnati, OH 45229, USA
e-mail: leah.kottyan@cchmc.org
Genome wide association studies have identified variants in PXK that confer risk
or humoral autoimmune diseases, including systemic lupus erythematosus (SLE
r lupus), rheumatoid arthritis and more recently systemic sclerosis. While PXK
s involved in trafficking of epidermal growth factor Receptor (EGFR) in COS-7
ells, mechanisms linking PXK to lupus pathophysiology have remained undefined.
n an effort to uncover the mechanism at this locus that increases lupus-risk, we
ndertook a fine-mapping analysis in a large multi-ancestral study of lupus patients
nd controls. We define a large (257kb) common haplotype marking a single causal
ariant that confers lupus risk detected only in European ancestral populations and
pans the promoter through the 3′ UTR of PXK. The strongest association was found
t rs6445972 with P < 4.62 × 10−10, OR 0.81 (0.75–0.86). Using stepwise logistic
egression analysis, we demonstrate that one signal drives the genetic association
n the region. Bayesian analysis confirms our results, identifying a 95% credible
et consisting of 172 variants spanning 202 kb. Functionally, we found that PXK
perates on the B-cell antigen receptor (BCR); we confirmed that PXK influenced
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the risk haplotype exhibited a decreased rate of BCR internalization, a process known
to impact B cell survival and cell fate. Taken together, these data define a new candidate
mechanism for the genetic association of variants around PXK with lupus risk and highlight
the regulation of intracellular trafficking as a genetically regulated pathway mediating
human autoimmunity.
keywords: lupus, PXK, fine-mapping, B cells, BCR
INTRODUCTION
Systemic Lupus Erythematosus is the prototypical systemic
autoimmune disease. Consequently, considerable effort has been
devoted to understanding the genetic component of lupus risk.
Now an understanding of causal mechanisms is approaching 10%
of the 50 replicated genomic risk-loci that reach genome-wide
significance (Vaughn et al., 2012).
Using a genome-wide association study (GWAS) design, we
first identified association of a single nucleotide polymorphism
(SNP) in the PXK locus with the occurrence of lupus in women
of European descent (Harley et al., 2008). The PXK locus associ-
ation with lupus-risk has since been replicated in several studies
(Gateva et al., 2009; Suarez-Gestal et al., 2009). In these studies,
the same variant identified in the initial GWAS was assessed in
independent cohorts and the lupus-risk association was replicated
(Gateva et al., 2009; Suarez-Gestal et al., 2009). These studies
did not include any biological or functional genomic follow-up
of the replicated association of this variant (Gateva et al., 2009;
Suarez-Gestal et al., 2009). A fourth, recent study included a
moderately-powered fine mapping analysis of a European cohort
and used expression quantitative trait locus analysis of nearby
genes to argue for a role ofABHD6 in the increased lupus risk. For
the current analysis, we initiated a well-powered fine-mapping
study aimed at identifying the likely causal variants and defining
the biological mechanisms of lupus risk at this locus.
PXK is part of the sorting nexin (SNX) family of proteins,
which are important for receptor internalization, organelle traf-
ficking including endosomal trafficking, and other membrane-
centric sorting functions. This is accomplished primarily through
the PX-domain mediated binding of PI3P (Xu et al., 2001; Seet
and Hong, 2006). PXK was first identified and cloned by two
independent groups in 2005 (Mao et al., 2005; Zou et al., 2005).
Initial studies established that PXK is detectable in most tis-
sues with a primarily cytoplasmic distribution. A more recent
study in COS-7 cells demonstrated that PXK co-localized with
the EGFR. Furthermore, PXK facilitated EGFR internalization
following ligand binding, which was found to be PX-domain
dependent (Takeuchi et al., 2010; Pedersen et al., 2012). PXK
is widely expressed in the brain and blood (Zou et al., 2005),
especially in B cells (Figure S1).
In this study, we identify a 257 kb region on chromosome 3,
including all of PXK and a large region upstream of the gene that
contains the lupus association signal. These results are confirmed
via Bayesian analysis by which we identify a credible set consisting
of 172 variants that explain 95% of the posterior probability in the
region (Wellcome Trust Case Control Consortium et al., 2012).
Through step-wise logistic regression analysis, we demonstrate
that this region contains a single genetic effect.
Many studies in mice and humans highlight a central role
of B cells in the etiology of lupus. Using the transcriptome of
various B cell subsets, Hu et al. demonstrated that B cells and
especially transitional B cells are enriched for transcripts near
genetic variants associated with increased lupus risk (Hu et al.,
2011). Autoreactive B-cells play a critical role in the develop-
ment of autoantibodies that lead to immune complex deposition
and lupus-associated tissue damage (Grimaldi et al., 2005). In
murine studies, mice without B cells are largely protected from
lupus-like disease (Shlomchik et al., 1994). Furthermore, murine
studies established a clear role for B cells in the dysregulated
cytokine production and T cell activation associated with lupus-
like autoimmunity (Chan and Shlomchik, 1998; Chan et al.,
1999).
B cell signaling through the B cell receptor (BCR) plays
a critical role in the development of autoimmunity in lupus
(Chaturvedi et al., 2011; Heesters et al., 2014). For example, BCR
internalization facilitates Toll like receptor ligand internalization
and signaling. Furthermore, type I IFN- a key cytokine known
to play a role in lupus- is known to promote rapid BCR inter-
nalization (Chaturvedi et al., 2008; Giltiay et al., 2012). Based
on its role in regulating EGFR, we hypothesized that PXK par-
ticipates in BCR internalization and lupus-associated variants in
the PXK locus differentially regulate BCR internalization. Indeed,
we demonstrate that PXK colocalizes with the BCR and that the
risk variants are associated with a decrease in BCR internaliza-
tion. Knockdown of PXK replicates this phenotype, confirming
the direct involvement of PXK in BCR trafficking.
METHODS
SUBJECTS AND STUDY DESIGN
We used a large collection of samples from case-control subjects
from multiple ethnic groups. These samples were from the col-
laborative Large Lupus Association Study 2 (LLAS2) (Rasmussen
et al., 2011) and were contributed by participating institutions in
the United States, Asia, and Europe. According to genetic ances-
try, subjects were grouped into ethnic groups including European
American (EU), African American (AA), Asian and Asian
American (AS), and Hispanic American (HA). Informed con-
sent was obtained from all subjects using Institutional Regulatory
Board approved consent documents. All lupus patients met
the American College of Rheumatology (ACR) criteria for the
classification of lupus (Hochberg, 1997).
GENOTYPING OF GENETIC VARIANTS AND SAMPLE QUALITY
CONTROL
We genotyped 58 single-nucleotide polymorphisms (SNPs) cov-
ering the entire PXK region (58.1–58.5 MB on Chr 3, Build 37),
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as part of a larger custom genotyping study. The variants were
chosen based upon the results of a candidate association study of
720 women of European ancestry and 2337 controls (Harley et al.,
2008). Specifically, the variants were chosen to span the associa-
tion interval identified with the Infinium HumanHap330 array.
Genotyping of SNPs was completed with Infinium chemistry on
an Illumina iSelect custom array according to the manufacturer’s
protocol. The following quality-control procedures were imple-
mented to identify SNPs for analysis: well-defined clusters for
genotype calling, call rate >90% across all samples genotyped,
minor allele frequency (MAF) >1% (except for the rare variant
analysis as described below), and p > 0.05 for differential miss-
ingness between cases and controls (the total proportion missing
was<5%). Onemarker with evidence of a departure fromHardy-
Weinberg proportion expectation (p < 0.0001 in controls) was
removed from the initial analysis.
We removed individuals with a call rate <90% or excess het-
erozygosity. The remaining individuals were examined for exces-
sive allele sharing as estimated by identity-by-descent (IBD). In
sample pairs with excessive relatedness (IBD > 0.4), one individ-
ual was removed from the analysis on the basis of the following
criteria: (1) remove the sample with the lower call rate, (2)
remove the control and retain the case, (3) remove the male sam-
ple before the female sample, (4) remove the younger control
before the older control, and (5) in a situation with two cases,
remove the case with the less complete phenotype data available.
Discrepancies between self-reported and genetically determined
gender were evaluated.
ASCERTAINMENT OF POPULATION STRATIFICATION
Genetic outliers from each ethnic and/or racial group were
removed from further analysis as determined by principal com-
ponent (PC) analysis and admixture estimates (Figure 1 of
McKeigue et al., 2000; Price et al., 2006; Lessard et al., 2011). We
used 347 ancestral informative markers (AIMs) from the same
custom genotyping study that passed quality control in both
EIGENSTRAT (Price et al., 2006) and ADMIXMAP (Hoggart
et al., 2003, 2004) to distinguish the four continental ancestral
populations, allowing identification of the substructure within
the sample set (Smith et al., 2004; Halder et al., 2008). The AIMs
were selected to distinguish four continental ancestral popula-
tions: Africans, Europeans, American Indians, and East Asians.
We utilized principal components from EIGENSTRAT outputs to
identify outliers of each of the first three PCs for the individual
population clusters with visual inspection.
STATISTICAL ANALYSIS—WORKFLOW
The analysis was initiated by assessing the association of geno-
typed variants in each of the four ancestral cohorts individu-
ally as done previously at another locus (Kottyan et al., 2014).
Strategically, we analyzed the genotyped, then imputed variants,
performed full haplotype analysis, executed linkage disequilib-
rium analysis, and finally built a statistical model to account for
the lupus-associated variability in European ancestry. In building
the model of association in European Americans, we compara-
tively evaluated every variant in the region for its ability to better
account for the lupus-associated genetic variation.
STATISTICAL ANALYSIS—FREQUENTIST APPROACH
We tested each genetic variant for association with lupus
using logistic regression models (frequentist approach) that
included three admixture proportion estimates as covari-
ates as implemented in PLINK v 1.07 (Marchini et al.,
2007; Purcell et al., 2007). The additive genetic model is
the primary model of inheritance. Other models were sub-
sequently considered, but only if substantially superior. We
performed a Cochran-Armitage trend test, a genotypic test,
and tested both the dominant and recessive gene models.
Logistic regression using an additive model remained the best
model.
Step-wise logistic regression was performed to identify those
genetic variants independently associated with the development
of lupus in PLINK. For these analyses, the allelic dosage of a
specific variant was added to the logistic model as covariates
in addition to the admixture estimates. Haplotypic associations
were assessed using logistic regression incorporating admixture
measurements as covariates.
Linkage disequilibrium (LD) and haplotypes were determined
with PLINK and HAPLOVIEW v 4.2 (Barrett et al., 2005;
Sankararaman et al., 2008; Barrett, 2009). We calculated haplo-
type blocks for those haplotypes present at >3% frequency using
the 4 gamete rule algorithms with a minimum r2-value of 0.8.
Haplotypic associations were performed in PLINK using a 200 kb
sliding window approach.
STATISTICAL ANALYSIS—BAYESIAN APPROACH
Using SNPTEST, we calculated the Bayes factor (BF) for each
genetic variant: the probability of the genotype configuration
at that genetic variant in cases and controls under the alterna-
tive hypothesis that the variant is associated with disease sta-
tus divided by the probability of the genotype configuration
at that variant in cases and controls under the null hypothe-
sis that disease status is independent of genotype at that variant
as previously described (we used the methods developed and
introduced in Wellcome Trust Case Control Consortium et al.,
2012). We used three admixture estimates as covariates, as we
did for the frequentist approach. Large values of the Bayes fac-
tor (BF) correlate to robust evidence for association, as small
p-values correlate to strong evidence in a frequentist approach.
For our well-powered study, the Bayes factors (BFs) of the vari-
ants were highly correlated with the p-values (consistent with,
Stephens and Balding, 2009). We used the additive model. The
linear predictor is log(pi/(1-pi)) = µ+ ßGi, and the prior
is µ ∼N(0,12), ß∼N(0,0.22) (variables are defined in the supple-
mentary note in Wellcome Trust Case Control Consortium et al.,
2012).
To identify the variants most likely to be driving the statis-
tical association we calculated a posterior probability under the
assumption that any of the variants within a single genetic effect
could be causal and that only one of these variants is causal
for each genetic effect. Variants with a low posterior probability
are highly unlikely to be causal regardless of the allele frequency
or presence of the actual causal variant in the analysis, follow-
ing the procedure as presented (Wellcome Trust Case Control
Consortium et al., 2012).
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RE-SEQUENCING
We re-sequenced the PXK region as described previously (Lessard
et al., 2012). DNA from European American subjects included
in the current genotyping experiment was sequenced. To assess
the accuracy of sequence-based SNP calling, we cross-referenced
the sequenced and genotyped allele calls. Briefly, 3–5 micrograms
of whole genomic DNA from each sample was sheared and pre-
pared for sequencing with an Illumina Paired-End Genomic DNA
Sample Prep Kit. Targeted regions of interest from each sample
were then enriched with a SureSelect Target Enrichment System
utilizing a custom-designed bait pool (Agilent Technologies).
Post-sequence data were processed with Pipeline software v.1.7
(Illumina). All samples were sequenced to minimum average fold
coverage of 253. Variant detection and quality control were also
performed as previously described (Lessard et al., 2012).
IMPUTATION TO COMPOSITE 1000 GENOMES REFERENCE PANEL
To detect associated variants that were not directly genotyped, we
imputed the PXK region with IMPUTE2 and using a compos-
ite imputation reference panel based on 1000 Genomes Project
sequence data freezes from December 2013 (Marchini et al.,
2007; Altshuler et al., 2010; Lofgren et al., 2010). Imputed geno-
types were required to meet or exceed a probability threshold
of 0.5, and information measure of >0.4, and the same quality-
control criteria threshold described for the genotyped markers.
In the statistical analyses, the probability threshold from each
imputed value was incorporated into the statistical analysis using
SNPTEST. The overall genotype-imputed variant concordance
rate was >93%.
RARE VARIANT ANALYSIS
Rare variant analysis was performed in SVS Golden Helix SNP
and Variation Suite v7.6.10 on the re-sequenced dataset and
the imputed dataset. Rare variants were filtered based upon
call rate and minor allele frequency <0.01. The one-sided ker-
nel based adaptive cluster algorithm was performed using the
hyper geometric kernel type with 1000 permutations in SVS
GoldenHelix. For these studies, the initial analysis was per-
formed using sequencing data from 92 lupus cases and 114
controls. Because this initial study was underpowered to iden-
tify an increased rare variant burden, we extended this analysis
to an imputed dataset of all 4220 European lupus cases and 3803
European lupus controls. The accuracy of rare variant imputa-
tion, while limited, has been previously validated (Sung et al.,
2012; Chen et al., 2013).
POWER ANALYSIS
Power analysis was performed using the Genetic Power Calculator
(Purcell et al., 2003).
CELL CULTURE
Lymphoblastoid cell lines (LCLs) derived from control study par-
ticipants without lupus were generated as previously described
(Rasmussen et al., 2011) and maintained at 37◦C in RPMI 1640
media containing 10% heat-inactivated fetal bovine serum (FBS)
and antibiotic/antimicotic (Gibco/Life Technologies, Grand
Island, NY). Peripheral blood mononucelar cells (PBMCs) were
isolated using Ficoll-gradient centrifugation in SepMate tubes
(Stemcell Technologies, Vancouver, BC, Canada) from fresh
blood collected in acid citrate dextrose (ACD) tubes with
informed consent from healthy donors. B cells were isolated using
the B-cell isolation kit-II (Miltenyi Biotech, Auburn, CA).
RNA PURIFICATION AND EXPRESSION ANALYSIS
Total RNA was purified from LCLs using the RNeasy kit
(Qiagen Valencia, CA). RNA was reverse-transcribed with the
High-Capacity RNA-to-cDNA kit (Applied Biosystems, Grand
Island, NY). Gene expression was determined by real-time PCR
using a 7500 Real-time PCR system or Viia 7 system (Applied
Biosystems). Relative quantification was calculated by the com-
parative CT method (Livak and Schmittgen, 2001). Briefly,
expression levels for each target were normalized to levels of
18S ribosomal rRNA in the same well. All samples were then
normalized to a selected sample and the data was exponentially
transformed.
Protein expression was quantified in LCLs by flow cytom-
etry. Cells were permeabilized and stained using reagents
from Beckton, Dickinson and Company (BD, Franklin Lakes,
NJ). Following staining, fluorescence was determined on an
LSRFortessa analyzer (BD). The geometric median fluorescence
intensity (gMFI) was calculated in FlowJo (Tree Star, Ashland,
OR) and used as an estimate of protein expression. All experi-
ments were run in triplicate. Statistical analysis and data visual-
ization were done with GraphPad Prism (GraphPad Sftward, La
Jolla, CA).
BCR INTERNALIZATION AND COLOCALIZATION
BCR internalization was adopted from the method described by
Malhotra et al. (2009a,b). Briefly, LCLs or freshly isolated PBMCs
from subjects without lupus were incubated with anti-BCR for
30min at 4◦C. Cells were then placed at 37◦C for the indi-
cated times. Cross-linked BCR remaining on the surface was then
detected with fluorescently labeled secondary antibody with the
LSRFortessa Cell Analyzer. Percent internalization was obtained
by measuring the gMFI at each time point and then calculating
the change as follows: (gMFI no internalization (4◦ sample) –
gMFI internalization (37◦ sample)) ÷ (gMFI no internalization
(4◦ sample)) × 100. Statistical analysis was performed in R using
the packages “nlme” and “lmerTest.” Cells were imaged with a
confocal microscope and the ImageStreamX (Amnis, Seattle, WA)
for co-localization analysis. All experiments were run in triplicate.
shRNA TRANSFECTIONS
shRNA were obtained from the CCHMC Lenti-shRNA Library
Core, utilizing the Sigma Mission system. Viral vector DNA
was isolated using Endofree Plasmid Maxi Prep kits (Qiagen).
Lentiviral transduction was performed by the CCHMC Viral
Vector Core. Viral particles containing the shRNAs were used
to transfect LCLs from control subjects. Cells were plated onto
retronectin-coated plates, viral particle supernatant added, and
spun for 45min at 1300 × G at 22◦C. After resting at 37◦C
overnight, spinfection was repeated. Cells were transferred to
selection media containing 2 ug/ml puromycin after 48 h. After
non-transfected cells began to die (approximately 3–5 days)
cells were tested for PXK expression and maintained for use in
subsequent experiments.
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MATERIALS
Anti-BCR (F(ab′)2 antibodies to IgG/IgM and Alexa Fluor 647-
conjugated donkey anti-human IgG/IgM) were from Jackson
ImmunoResearch (West Grove, PA). Anti-PXK antibody was pur-
chased from Abcam (Cambridge, MA). Anti-LAMP1 antibody
was purchased from BioLegend (San Diego, CA). Secondary anti-
bodies were purchased from Life Technologies (Carlsbad, CA).
Retronectin was purchased from Clonetech (Mountain View,
CA). Puromycin was purchased from Invivogen (San Diego, CA).
All other antibiotics and cell culture reagents were purchased
from HyClone (Logan, UT) and Gibco (Life Technologies).
Quantitative PCR was performed using TaqMan probes from Life
Technologies.
RESULTS
We genotyped 57 useful markers from the PXK locus in a tran-
sancestral group of 18,286 lupus cases and controls. Our study
included 8023 individuals of European descent (EA), 3740 indi-
viduals of African American descent (AA), 2481 individuals of
Hispanic American descent (HA) and 2652 individuals of Asian
descent (AS). To better capture the total variation in the locus,
we imputed against a composite reference panel derived from the
1000 Genomes Project (Howie et al., 2011) for a final dataset
of 269–835 variant markers, depending on ancestry, all with a
minor allele frequency (MAF) greater than 0.01 (Table 1).We per-
formed logistic regression analysis to reveal a large association
region of 257 kb extending from just upstream of PXK begin-
ning in ABHD6 and extending through RPP14 in individuals
of European descent (Figure 1A). Overall, the most significant
SNP was rs6445972 with P < 4.62 × 10−10, OR 0.81 (0.75–0.86).
The most significant, directly genotyped SNP was rs4681677
with P < 2.00 × 10−9, OR 0.81 (0.76–0.87). Because rs4681677
was genotyped and not assessed solely through imputation, we
used this SNP to classify cell lines as risk or protective for sub-
sequent biological experiments. We found no evidence of the
lupus-association at this locus in the other populations studied
(Figure 1B). rs6445972 has an allele frequency of 30.0% in the
EA cohort, 10.4% in the AA cohort, 22.9% in the HA cohort,
and 0.2% in the AS cohort, suggesting that a largely European-
derived allele is driving the very modest statistical association in
the cohorts with European admixture.
Analysis of linkage disequilibrium (LD) in the region
revealed high LD between the most strongly associated variants
(Figure 2A). No single haplotype (using either blocks constructed
from continuous groups of variants or the most highly associ-
ated variants) outperformed the single variant association model
(data not shown), supporting the conclusion that the association
in the region is due to a single genetic variant. In a complementary
Bayesian analysis, we find a similar pattern of association, consis-
tent with results from our frequentist logistic regression analysis.
The 95% credible set (Wellcome Trust Case Control Consortium
et al., 2012) contains 172 variants spanning a 202 kb region (chr
3: 58261741-58463411) (Figure 2B).
To identify candidate variants in the EA population, we per-
formed stepwise logistic regression to evaluate the ability of
variants within the associated haplotype to explain all of the
lupus-associated variation. Adjusting for any one of the top
variants in the region eliminated the association signal, support-
ing the model that there is only one association in the region
(Figure 3).We sequentially tested each variant in our dataset indi-
vidually in our conditional analysis in an attempt to isolate groups
of variants that may disproportionately carry the association sig-
nal in the region. While we did find clear groups, we found those
variants that were able to adjust for the largest portion of the
lupus-associated variation were in high LD (r2 > 0.8) with the
most strongly associated variants. Notably, the SNP identified in
our original GWAS study, rs6445975, did not account for lupus
risk as completely as the most strongly associated variants in the
current study (Figure 3 and Figure S2).
It remained possible that rare variants were driving the lupus
association at the PXK locus. To test this possibility, we performed
deep sequencing of the region in 92 cases and 114 controls of
European ancestry. We found no statistical association of any of
the variants with frequencies less than one percent using a logis-
tic regression analysis with an additive model; furthermore, we
found no increased burden of rare variants in any of the genes in
the region in the cases compared to the controls (data not shown).
Despite the limitations of imputed rare variants, we repeated the
rare variant burden test on the complete European population
and did not find evidence of increased rare variants in the lupus
cases.
In order to assess the hypothesis that lupus-associated vari-
ants were affecting the gene expression, we measured expression
levels of all 5 genes in transformed B cell lines from control sub-
jects and found no difference between cell lines with homozygous
risk and homozygous non-risk genotypes (Figure S3). We did not
find any difference in mRNA or total PXK protein expression
(Figures 4A,B).
PXK is highly expressed in the B cell lineage, with the high-
est expression in mice observed in both transitional and follicular
splenic B cells (Hu et al., 2011). The transitional B cell was recently
implicated as one of the cell types critical to lupus pathogenesis
Table 1 | Summary statistics for each study population.
Population Case Control Male Female Genotyped Imputed (MAF > 0.01)
European (EA) 4220 3803 1696 6327 57 477
African American (AA) 1719 2021 766 2974 57 835
Hispanic (HA) 1599 882 244 2237 57 593
Asian (AS) 1310 1342 301 2351 57 269
Cleaning steps are described in methods.
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FIGURE 1 | Variants in the PXK locus are associated with lupus. (A) Plot
of –log10(p) values for directly genotyped (red) and imputed (blue) SNPs
spanning the previously identified region of association with lupus. Gene
locations are indicated above with arrows indicating direction of transcription.
(B) Plot of –log10(p) values for different ancestral cohorts. EA, European
ancestry; AA, African American ancestry; HA, Hispanic and Amerindian
ancestry; AS, Asian ancestry. While not the most highly associated SNP,
rs4681677 (purple) was used to choose samples for biological studies
because it was genotyped; this SNP is in high LD (r2 > 0.9) with the imputed
SNPs that are more highly associated.
based on a combined genetic and cell-specific expression analysis
(Ramos et al., 2011). Given the expression of PXK in B cells, the
fact that PXK has been shown to play a role regulating cell sur-
face receptor expression, and the importance of B cells to the
pathology of lupus, we hypothesized that PXK participates in
the internalization of the BCR. We first evaluated colocalization
between PXK and the BCR in B cells following BCR crosslinking
on the cell surface. We found moderate steady-state colocal-
ization between PXK and the BCR at baseline that increased
following BCR crosslinking and continued to increase with cel-
lular internalization (Figure 5). We then tested the hypothesis
that the lupus-associated risk variants at the PXK locus affected
the rate of BCR internalization by measuring the internaliza-
tion of the BCR in cells derived from individuals with known
genotypes. Following BCR crosslinking, we measured receptor
internalization with flow cytometry and found that cells carrying
the homozygous risk genotype displayed a decrease in the amount
of BCR internalization compared to cells homozygous for the pro-
tective genotype (Figure 6). This finding was consistent across all
the measurements over the time course of the experiment.
To assess the role of PXK in the BCR internalization pheno-
type, we decreased PXK expression using shRNA by transfecting
Frontiers in Genetics | Statistical Genetics and Methodology January 2015 | Volume 5 | Article 450 | 6
Vaughn et al. PXK variants alter BCR internalization
FIGURE 2 | Evaluation of linkage disequilibrium in the PXK locus
and Bayesian association analysis. (A) Association plot of genotyped
and imputed SNPs shaded to identify the significant LD in the region.
Colors correspond to r2-values, with darker shade indicating higher
r2-values. (B) Bayesian analysis of variants in the PXK locus. Plot of
posterior probability calculated for each variant in the locus. Variants
included in the 95% credible set based on posterior probabilities are
colored green.
5 study-derived cell lines from patient without lupus with
shRNA targeted against PXK or scrambled controls (Figure 7A).
Knockdown of PXK resulted in reduced internalization of
the BCR, especially at the early time points (Figure 7B), and
this reduction was directly correlated with PXK expression
(Figure 7C).
DISCUSSION
We performed a fine-mapping study to define the genetic variants
and the gene most likely to be causal for increased lupus risk. We
genotyped 18,286 cases and controls from four ancestral popula-
tions, leveraging imputation to increase our coverage of the target
locus. We used both logistic regression, and Bayesian methods to
verify our findings that the disease risk from this locus is due
to highly correlated variants in a large region including PXK.
Additionally, we complemented our genetic fine-mapping with
biological experiments, identifying a genotypic change in BCR
internalization that is associated with the presence of lupus-risk
variants.
Analysis of the PXK locus in non-European populations
revealed no significant association in the region (Figure 1B).
The allele frequency of the most highly associated variants dif-
fered amongst the ancestral groups, and given the observed
allele frequencies, power analysis indicates that a much larger
non-European population will be needed to detect a similar asso-
ciation of this magnitude at this locus (data not shown). Thus,
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FIGURE 3 | Step-wise logistic regression analysis reveals one independent genetic effect at the PXK locus. Plot of P values (–log10) following adjustment
for genotype at rs4681677. Adjustment for other SNPs with r2 > 0.9 with rs4681677 can also account for the genetic association (P < 0.01) in the region.
FIGURE 4 | PXK expression in cell lines derived from study
participants. (A) Plot of Ct values of PXK mRNA expression using
TaqMan probes. (n = 14 risk/14 protective) (B) PXK expression at the
protein level using flow cytometetry. (n = 8 homozygous risk/5
homozygous protective). Data for both A and B are representative of 3
independent experiments using control cell lines. Statistical analysis using a
Student’s t-test was performed in PRISM.
FIGURE 5 | PXK colocalizes with the BCR following receptor
crosslinking. (A) Quantification of colocalization between PXK and the
BCR following BCR crosslinking in primary B cells from subjects without
lupus. (B) Representative images showing colocalization. Statistical
analysis using a One-Way ANOVA was performed in PRISM.
the lack of an association in the other populations may be due
entirely to the difference in power.
We found a 50% decrease in BCR internalization kinet-
ics between risk and non-risk genotypes. This change in BCR
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FIGURE 6 | B cells carrying PXK risk allele demonstrate decreased
internalization of the BCR. (A) Representative flow cytometry histogram
showing decreasing fluorescence following internalization of the BCR from
the B cell surface using patient-derived LCLs. (B) Quantification of BCR
internalization as measured by the percent internalization (decrease in
gMFI) following receptor crosslinking. Results of linear mixed model
analysis as performed in R are shown. This experiment was performed
using 20 cell lines from subjects without lupus in three independent
experiments. The results of these independent experiments were
combined and presented in (B).
internalization may have a small effect in the regulation of B cell
signaling; however, it could also be meaningful in the context of
other additive changes to the B cell signaling pathway (Vaughn
et al., 2012). There are several mechanisms through which this
functional change could affect the risk of autoimmunity. For
example, stimuli that would be sufficient to develop strong B
cell activation with subsequent negative selection may now be
less likely to result in elimination due to attenuated BCR inter-
nalization. Indeed, the persistence of auto-reactive clones in the
periphery may play an important role in the context of lupus
pathogenesis.
PXK colocalized with the BCR and affected internalization,
indicating a potential role for PXK in the regulation of BCR
signaling. Importantly, the colocalization increased as the BCR
is internalized into the cell, suggesting a role for PXK beyond
the cell surface. Furthermore, we find that cells carrying the
FIGURE 7 | shRNA knockdown of PXK disrupts BCR colocalization.
(A) PXK protein expression following shRNA knockdown in 5 LCL lines
from non-lupus subjects (expression was assessed in triplicate for each
cell line). (B) Summary of BCR internalization at 2min in LCLs following
viral transduction with either an shRNA against PXK or a scrambled
control. Results from unpaired Student’s t-test shown. (C) Correlation
between PXK protein expression and BCR internalization following
shRNA knockdown. The significance was assessed using a Pearson
correlation. The graphs in (B,C) are representative of the results of three
independent experiments.
lupus-risk haplotype have a decreased amount of BCR inter-
nalization when compared to cell lines carrying the non-risk
haplotype, an allelic functional change that we present as a
candidate causal mechanism of increased lupus risk at this
locus.
When PXK is specifically knocked down using shRNA, BCR
internalization is decreased, confirming a clear role for PXK in
regulating BCR internalization. These results support the con-
clusion that the allele-specific changes in BCR internalization
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we detect are most likely attributable to PXK. We do not yet
understand the genetic mechanism behind this alteration in
BCR internalization. We were unable to detect a difference in
overall PXK expression. It may be that some other molec-
ular differences are occurring after PXK expression, such as
alternative splicing or differential post-translational modifica-
tion. Future studies will be directed at detecting these changes.
While ABHD6 eQTLs were shown to correlate with lupus-
association, there were also PXK eQTLs that were associated
with lupus (Oparina et al., 2014). The PXK locus remains
complicated and future work will be important to continue
to unravel the specific genetic variations underlying the lupus
association.
We and others refer to this locus as the “PXK locus” (Graham
et al., 2008; Harley et al., 2008; Suarez-Gestal et al., 2009;
Ramos et al., 2011; Oparina et al., 2014). Although our step-
wise logistic regression analysis of common variants (Figure 3)
makes it unlikely, it is still possible that there is a contribu-
tion of rare variant(s) that we missed. Of the 5 genes in the
region, PXK and DNase1l3 are the only genes with apprecia-
ble expression in immune cells based on evaluation of public
databases (data not shown). DNASE1L3 encodes the protein
DNase 1-like 3, and is the only gene that has been investigated
functionally in the context of lupus. A loss-of-function frameshift
mutation in DNASE1L3 was found to be associated with early-
onset lupus and lack of detectable DNASE1L3 transcripts in an
autosomal recessive manner in six families of Arab descent (Al-
Mayouf et al., 2011). DNASE1L3 was also recently identified as
a risk gene in systemic sclerosis (Mayes et al., 2014). The vari-
ant identified in that study shows no association with lupus
in our dataset (p = 0.3067). DNASE1L3 is removed from the
peak association in the frequentist, logistic regression analysis
and no members of the 95% credible set in the Bayesian anal-
ysis were located in or within 25 kb of DNASE1L3. It remains
possible that variants many hundreds of killobases away from
the promoter of a gene could affect that genes transcription
(Westra et al., 2013); however, while both of our groups found
detectable DNASE1L3 transcripts, neither our group nor other
groups have identified allelic expression of DNASE1L3 in our
cell lines (Oparina et al., 2014). Of the remaining genes, ABHD6
has recently been suggested as the causal gene responsible for
the association with lupus at this locus (Oparina et al., 2014).
Mutations in ABHD6 have been associated with multiple non-
autoimmune phenotypes (Blankman et al., 2007; Alhouayek
et al., 2013; Tchantchou and Zhang, 2013; Thomas et al., 2013;
Volk et al., 2013), but beyond ABHD6 being in the associated
region there is no evidence, at present, for ABHD6 in lupus
pathogenesis.
Overall, we identified a limited haplotype of highly associated
variants in the promoter and first exon of PXK that account for all
of the lupus-association in the region. We performed biochemical
analysis to demonstrate that PXK co-localizes with the BCR and
affects BCR internalization. Furthermore, we identified an allelic
decrease in PXK-BCR co-localization and BCR internalization in
subjects expressing the lupus-risk haplotype. Taken together, our
work supports amodel in which PXK increases lupus risk through
the regulation of BCR internalization.
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